Contributions
Abstract: PB1823
Type: Publication Only
Session title: Thrombosis and vascular biology - Biology & Translational Research
Background
Diabetes is a metabolic syndrome that generates an increase in glucose levels, so diabetic patients have been associated with the development of hemostatic complications, such as endothelial and platelet dysfunctions, coagulation factors, natural anticoagulants and the fibrinolytic system. They are also more prone to hypercoagulability cases.
Aims
This systematic review aims on how diabetes mellitus affects hemostatic changes.
Methods
Three electronic databases (SciELO, LILACS, PubMed) were consulted in search for articles, published in the last five years, using the following keywords searched in DeCs/MeSH: diabetes mellitus, hemostasis, blood disease.
The initial online search led to the retrieval of 1.248 references and reviewers extracted data independently. A total of 10 articles were used in the review. The checklist of 27 items and 4-step flow chart (Table 1) indicated by the PRISMA methodology were used.
Results
The study by Wieczór, R. et al. (2019) evaluated patients with symptomatic peripheral arterial disease and demonstrated that the concomitance of this disease with DM2 contributes to an increase in the concentration of fibrinogen in the blood. Pretorius, Thomson et al (2018) also reported that the presence of amyloid fibrin, the increase in circulating inflammatory biomarkers and a hyperglycemic state contributes to blood hypercoagulability. Greenhalgh, KA, et al. (2017) shows a brief connection between a variant of fibrinogen present in diabetics and significant changes in the structure of the clot and fibrinolysis, resulting in dense fibrin networks, difficult to lyse.
It is observed in the study by Sumaya, W et al. (2020) that individuals with diabetes may have changes in their lipid profile, converging to cases of lipotoxicity and changes in fibrinolysis. According to IS Sobzkak and Stewart, A (2019) 80% of patients with diabetes die from cardiovascular events. The randomized test conducted by Bratsheth, V et al. (2017) shows that physical exercise in one year was not able to bring greater control over pro-coagulant disorders and more serious diseases, such as albuminuria and acute myocardial infarction. However, research by Patti, G., Cavallari, I., Andreotti, F. et al. (2019) shows that more aggressive antithrombotic strategies can be indicated for diabetics with cardiovascular diseases.
The study by Gajos, G., Siniarski, A., et al. (2018) analyzed patients with DM2 and concluded that inadequate glycemic control, with increased platelet activation and oxidative stress, causes an increase in the formation of polyhedrocytes in contracted blood clots.
Newman, JD et al. (2017) evidenced that the glucose concentrations in the patient with DM potentiate the activation of the platelet-megakaryocyte hemostatic axis allowing the inorganic arsenic to cause atherothrombotic risk in diabetic patients.
The study by Bryk, AH, et al. (2019) showed that the markers of extracellular neutrophil traps in circulating plasma are related to glycemic control, so that the detectable increase refers to a prothrombotic state, especially hypofibrinolysis in patients with DM2.
Conclusion
The analyzed articles call attention to the changes in the coagulation patterns and in the lipid profile of the diabetic, situations that may imply the occurrence of cardiovascular and atherothrombotic events, responsible for increasing the population's morbidity and mortality.
Keyword(s):
Abstract: PB1823
Type: Publication Only
Session title: Thrombosis and vascular biology - Biology & Translational Research
Background
Diabetes is a metabolic syndrome that generates an increase in glucose levels, so diabetic patients have been associated with the development of hemostatic complications, such as endothelial and platelet dysfunctions, coagulation factors, natural anticoagulants and the fibrinolytic system. They are also more prone to hypercoagulability cases.
Aims
This systematic review aims on how diabetes mellitus affects hemostatic changes.
Methods
Three electronic databases (SciELO, LILACS, PubMed) were consulted in search for articles, published in the last five years, using the following keywords searched in DeCs/MeSH: diabetes mellitus, hemostasis, blood disease.
The initial online search led to the retrieval of 1.248 references and reviewers extracted data independently. A total of 10 articles were used in the review. The checklist of 27 items and 4-step flow chart (Table 1) indicated by the PRISMA methodology were used.
Results
The study by Wieczór, R. et al. (2019) evaluated patients with symptomatic peripheral arterial disease and demonstrated that the concomitance of this disease with DM2 contributes to an increase in the concentration of fibrinogen in the blood. Pretorius, Thomson et al (2018) also reported that the presence of amyloid fibrin, the increase in circulating inflammatory biomarkers and a hyperglycemic state contributes to blood hypercoagulability. Greenhalgh, KA, et al. (2017) shows a brief connection between a variant of fibrinogen present in diabetics and significant changes in the structure of the clot and fibrinolysis, resulting in dense fibrin networks, difficult to lyse.
It is observed in the study by Sumaya, W et al. (2020) that individuals with diabetes may have changes in their lipid profile, converging to cases of lipotoxicity and changes in fibrinolysis. According to IS Sobzkak and Stewart, A (2019) 80% of patients with diabetes die from cardiovascular events. The randomized test conducted by Bratsheth, V et al. (2017) shows that physical exercise in one year was not able to bring greater control over pro-coagulant disorders and more serious diseases, such as albuminuria and acute myocardial infarction. However, research by Patti, G., Cavallari, I., Andreotti, F. et al. (2019) shows that more aggressive antithrombotic strategies can be indicated for diabetics with cardiovascular diseases.
The study by Gajos, G., Siniarski, A., et al. (2018) analyzed patients with DM2 and concluded that inadequate glycemic control, with increased platelet activation and oxidative stress, causes an increase in the formation of polyhedrocytes in contracted blood clots.
Newman, JD et al. (2017) evidenced that the glucose concentrations in the patient with DM potentiate the activation of the platelet-megakaryocyte hemostatic axis allowing the inorganic arsenic to cause atherothrombotic risk in diabetic patients.
The study by Bryk, AH, et al. (2019) showed that the markers of extracellular neutrophil traps in circulating plasma are related to glycemic control, so that the detectable increase refers to a prothrombotic state, especially hypofibrinolysis in patients with DM2.
Conclusion
The analyzed articles call attention to the changes in the coagulation patterns and in the lipid profile of the diabetic, situations that may imply the occurrence of cardiovascular and atherothrombotic events, responsible for increasing the population's morbidity and mortality.
Keyword(s):